This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled
trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of
schizophrenia, schizoaffective or schizophreniform disorder. This pilot study aims to provide
preliminary estimates of whether the effect sizes of dipyridamole on positive symptoms,
negative symptoms, and cognitive deficits differ between schizophrenia patients treated with
dipyridamole, and schizophrenia patients treated with olanzapine. A total of 30 subjects will
be recruited locally.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore